Replies to post #327695 on Amarin Corp Plc (AMRN)

[dmlcento]

If they win every argument then not only will Hikma be on the hook, but so will Helathnet. It won't take too many insurance companies having to fork over revenues to get them to stop pushing generics for indications that the generic shouldn't be selling.

[Number sleven]

HDG, I understand what you are trying to say. FDA has given 3 generic companies the right to sell their version of Vascepa in the US. If the court rules against Hikma do you think they will just keep selling gv? If Health net is hit with damages do you think they (or any other insurance company) will continue to reimburse costs of gv for the CVD indication? It is for the courts to decide if laws are being broken. What do you think will happen if the court does in fact make that determination here?
Sleven,

[Whalatane]

Well I'l leave it to the attorneys on this board to opine on how the order will be written if AMRN prevails against Hikma / HealthNet .
I would expect some very clear labeling on Hikma's product plus possible fines and HealthNet and others will be incentivized to ensure that Hikma's generic V did not go to R-IT indications .
Should AMRN prevail it will send a message to Dr Reddy that AMRN can successfully pursue any violation of their patent rights and will probably monitor the sales of their generic V .
If AMRN fails to prevail against Hikma/HelathNet ...it sends a message that there's less legal risk entering the US market
Kiwi

[studythosestocks]

Quote, "Hikma or any of the generics can sell their product for he high trigs >500 indication only already ..." True that is what has been declared but they are not only selling it for the >500 trigs only. With a court win they will not only have to pay us for the stolen scripts but also for damages much greater than just the product. I think this would be a great detriment to them or any other company wanting to push their generics. Also it is clear with the way the payor/pharmacy/generics work that there is collusion here. (you may disagree but I feel confident that it is. It is just a matter if we can prove this or not). If we win, what other payors are going to risk selling generics except only for the hypertrig indication. I believe that the generics on level 1 will be only for this indication and lower tiered V will be for the reduce it indication.
"Do you expect the 10% lose only?" That is my hope with the understanding that we will sue anyone and everyone who markets/sells gV for any indication other than hypertrigs. I understand that this may create a major revamping on payor/insurance situations. This is why I am wary that we win since it will create such a major turmoil in how insurance companies and generics do business.
"Do you expect no generic will be dispensed outside of the high trigs >500 indication?" If they do, there will be a price to be paid.
Quote:
"? No generic for R-IT indication ... Do you expect that gV will be dropped from Tier 1" Correct, no generic for R-It indication. There will still be a Tier 1 generic for the hypertrig indication. Once again, winning this lawsuit would completely overturn the apple cart in payor/pharmacy/generic/patient relationships. I don't think the justice system wants to touch this right now. I thought our arguments in the ITC trial were very strong but I didn't feel that the 3 justices wanted to trump the FDA and decided to let the FDA figure it out at their own pace (which they still haven't done being so short handed and this not being a priority). Once again. JMO. Gotta run, got a full slate of patients this afternoon. Take care, stay safe and appreciate your analysis.

Best,